中文名 | GSK2801 |
英文名 | GSK2801 |
别名 | 化合物GSK2801 BAZ2A和BAZ2B抑制剂(GSK2801) 1-(1-(2-(甲磺酰)苯基)-7-丙氧基吲哚嗪-3-基)乙酮 1-[1-[2-(甲基磺酰基)苯基]-7-丙氧基-3-吲哚嗪基]乙酮 |
英文别名 | GSK2801 GSK 2801 GSK-2801 GSK2801 GSK-2801 1-[1-[2-(Methylsulfonyl)phenyl]-7-propoxy-3-indolizinyl]ethanone 1-(1-(2-(methylsulfonyl)phenyl)-7-propoxyindolizin-3-yl)ethanone 1-[1-(2-Methanesulfonyl-phenyl)-7-propoxy-indolizin-3-yl]-ethanone 1-(7-(2-Methylsulfonyl-phenyl)-4-propoxy-1-aza-bicyclo[4.3.0]nona-2,4,6,8-tetraen-9-yl)-ethanone |
CAS | 1619994-68-1 |
化学式 | C20 H21 N O4 S |
分子量 | 371.45 |
密度 | 1.23±0.1 g/cm3(Predicted) |
溶解度 | 10毫米DMSO |
存储条件 | -20°C |
体外研究 | GSK2801 binds TAF1L(2) with an affinity K B of 0.31μM (K D : 3.2 μM) and a binding enthalpy change ΔH of −8.6 kcal/mol. ITC experiments using the bromodomain of BRD9 results in the determination of an affinity K B of 0.826 μM (K D : 1.1 μM) and ΔH of −9.8 kcal/mol. GSK2801 or RNAi knockdown of BAZ2A/B with JQ1 selectively displaced BRD2 at promoters/enhancers of ETS-regulated genes. In 2D cultures, enhances displacement of BRD2 from chromatin by combination drug treatment induced senescence. In spheroid cultures, combination treatment induces cleaved caspase-3 and cleaved PARP characteristic of apoptosis in tumor cells. Thus, GSK2801 blocks BRD2-driven transcription in combination with BET inhibitor and induces apoptosis of TNBC. |
体内研究 | In order to determine the suitability of GSK2801 for in vivo experiments, pharmacokinetic parameters after intraperitoneal and oral dosing to male CD1 mice is measured. GSK2801 has reasonable in vivo exposure after oral dosing, modest clearance, and reasonable plasma stability. |
危险品标志 | Xn - 有害物品 |
风险术语 | 22 - 吞食有害。 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.692 ml | 13.461 ml | 26.922 ml |
5 mM | 0.538 ml | 2.692 ml | 5.384 ml |
10 mM | 0.269 ml | 1.346 ml | 2.692 ml |
5 mM | 0.054 ml | 0.269 ml | 0.538 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!